RESEARCH MONOGRAPH · KDC-MN-378

Amphetamine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

78/100

The reference monoamine releaser; mechanism is textbook, the abuse liability is the whole conversation

Amphetamine is the reference compound for the entire phenethylamine releaser class. Substrate for the dopamine and norepinephrine transporters, accumulates in vesicles, displaces stored monoamines into the cytosol, and reverses transporter direction so monoamines flood back into the synapse. Also a weak MAO inhibitor at higher concentrations. That's the textbook mechanism and it has not changed in seventy years.

The clinical story is also old: racemic amphetamine (Adderall is roughly 3:1 d:l mix as the salts) has solid phase 3 data for ADHD in children and adults, with response rates in the 70 percent range and effect sizes that embarrass most psychiatric drugs. Cognitive effects in non-ADHD populations are smaller and more controversial. The Ilieva meta-analyses suggest a modest effect on working memory and inhibitory control in healthy adults, basically what you'd expect from a moderate dopamine boost.

What we like about it as a research tool: the pharmacology is so well characterized that it's the positive control in basically every in vivo dopaminergic experiment ever run. The d-isomer is more dopaminergic, the l-isomer is more noradrenergic, the racemate sits in the middle, and the receptor downstream effects are mappable.

What we don't like is honestly more about how the literature talks about cognitive enhancement than about the molecule itself. The chronic neurotoxicity story (Ricaurte's monkey work, the dopamine terminal damage at high repeated doses) is real but happens at exposures far beyond therapeutic. The lower-dose chronic question, neurogenesis and trophic factor changes, is more interesting and less settled.

Sourcing for research is a regulated nightmare in most jurisdictions. Schedule II in the US, equivalent in Europe. Reference standards are available through legitimate channels with the right licensing, and pharmacopoeia-grade material is unambiguous in purity. Just expect paperwork.

Staying power is high because the mechanism is foundational, every new monoamine releaser gets compared to it, and ADHD pharmacology hasnt moved beyond the stimulant class in any meaningful way despite decades of trying.

Evidence: 92
Mechanism: 92
Reliability: 88
Safety: 55
Sourcing: 60
Value: 65
Signal: 85
Staying power: 88

Plain-language summary Intrigue 75 / 100

Amphetamine is the prototype phenethylamine stimulant and the foundational compound for an entire pharmacological class. First synthesized in 1887 and developed clinically as Benzedrine in the 1930s, it works by reversing the transporters that normally pull dopamine, norepinephrine, and serotonin out of the synapse. Instead of inhibiting reuptake, it forces these neurotransmitters to flow outward, raising synaptic levels. Sold as Adderall (mixed salts), Dexedrine, and Evekeo for ADHD and narcolepsy. The two enantiomers behave differently: d-amphetamine is more dopaminergic and CNS-focused, l-amphetamine has stronger peripheral norepinephrine effects. Schedule II in the US with significant abuse potential. The canonical monoamine releaser in pharmacology research and a reference point for nearly every later phenethylamine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Phenethylamine monoamine releaser

The prototype phenethylamine stimulant; a monoamine releaser used in ADHD and narcolepsy and the foundation of an entire pharmacological class.

Abstract

Amphetamine ((R/S)-1-phenylpropan-2-amine; CAS 300-62-9; molecular formula C9H13N; molecular weight 135.21) is the prototype phenethylamine stimulant, first synthesized in 1887 by Edeleanu and clinically developed in the 1930s as Benzedrine. Mechanism: reversal of vesicular monoamine transporter 2 (VMAT2) and plasma membrane dopamine, norepinephrine, and serotonin transporters (DAT, NET, SERT), producing transporter-mediated efflux (release) rather than reuptake inhibition; the result is increased synaptic dopamine and norepinephrine concentrations. Secondary effects include MAO inhibition and TAAR1 agonism. The two enantiomers have differing pharmacology: d-amphetamine is more dopaminergic; l-amphetamine has greater peripheral noradrenergic activity. Approved indications: ADHD, narcolepsy, exogenous obesity (rare). Marketed as Adderall (mixed salts), Dexedrine (d-amphetamine), Evekeo (racemic). Plasma half-life is 9 to 14 hours. Schedule II in the US under the CSA. Used as the canonical monoamine releaser in pharmacology and the foundation for the broader phenethylamine class.

Mechanism of action

Reverses VMAT2, DAT, NET, SERT to produce transporter-mediated monoamine release. Secondary MAO inhibition and TAAR1 agonism. d-enantiomer more dopaminergic; l-enantiomer more noradrenergic.

Reported research dose ranges

Clinical 5 to 60 mg in the published literature or ER. Rodent research 0.5 to 5 mg/kg.

References

Sulzer D, et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005.
Heal DJ, et al. Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharmacol 2013.
Wilens TE, et al. ADHD treatment with OROS methylphenidate vs amphetamine salts. J Atten Disord 2006.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-378

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Amphetamine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs